← All trials
NCT04427930
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 13, 2020
- Primary completion
- Dec 23, 2026
- Completion date
- Dec 30, 2027
- First posted
- Jun 12, 2020
- Last posted
- Jun 12, 2020
- Enrollment
- 260
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- R-BiopharmLead sponsor
- Chonbuk National UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Yeungnam UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Keimyung UniversityOverall official - principal investigator
- Gyeongsang UniversityOverall official - principal investigator
- Chunang University HospitalOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.